Biogen News and Research

RSS
North Carolina Biotechnology Center awarded a transformational grant by the Biogen Idec Foundation

North Carolina Biotechnology Center awarded a transformational grant by the Biogen Idec Foundation

Biogen Idec restates its plan to purchase all outstanding shares of Facet Biotech

Biogen Idec restates its plan to purchase all outstanding shares of Facet Biotech

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

Biogen Idec offers to completely acquire Facet

Biogen Idec offers to completely acquire Facet

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Aaron Whiteman to be the new CEO of GENova Biotherapeutics

Aaron Whiteman to be the new CEO of GENova Biotherapeutics

Massachusetts to restore immigrant health care, Colorado Medicaid list grows, Obama in North Carolina

Massachusetts to restore immigrant health care, Colorado Medicaid list grows, Obama in North Carolina

Costly biologics drugs prompt exclusivity debate

Costly biologics drugs prompt exclusivity debate

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Rituximab linked to viral brain infection

Rituximab linked to viral brain infection

FDA warns 14 pharmaceutical companies about short internet ads lacking risk information

FDA warns 14 pharmaceutical companies about short internet ads lacking risk information

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Stromedix awarded U.S. patent for antibody-based therapeutics

Stromedix awarded U.S. patent for antibody-based therapeutics

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

FDA accepts Zevalin supplemental biologics license application

FDA accepts Zevalin supplemental biologics license application

FDA approves Tysabri to treat Crohn's disease

FDA approves Tysabri to treat Crohn's disease

Renewed search for lupus treatments and cure

Renewed search for lupus treatments and cure

Rituximab reduces disease activity in multiple sclerosis

Rituximab reduces disease activity in multiple sclerosis

Lawmakers have proposed 'witch's brew' of biotech bills

Lawmakers have proposed 'witch's brew' of biotech bills

New discoveries about stem cells in leukemia, breast and colon cancer

New discoveries about stem cells in leukemia, breast and colon cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.